Literature DB >> 11893009

Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.

Pu-Tsui Wang1, Robert Kuo-kuang Lee, Jin-Tsung Su, Jen-Wan Hou, Ming-Huei Lin, Yu-Ming Hu.   

Abstract

PURPOSE: This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor responders to standard long protocols of GnRHa administration.
METHODS: From Dec 1996 to Nov 1998, 50 patients who were classified as "poor responders" were scheduled for 52 cycles of a modified controlled ovarian hyperstimulation protocol. They were categorized into 3 groups: a group of poor responders to COH in the previous IVF or IUI cycles, a group with elevated Day 3 FSH levels, and a group over the age of 40 years. All patients received GnRH agonist from the midluteal phase of the previous cycle to the onset of menstruation in the next cycle. Then high doses of gonadotropins (HMG/FSH) were given. The patients then had standard courses of in vitro fertilization and embryo transfer (IVF-ET) or transfallopian embryo transfer (TET).
RESULTS: Six of the 52 cycles of the modified protocols were cancelled because of poor ovarian response. One premature ovulation was noted before ovum retrieval was performed. In the other 45 cycles, an average of 6.3 mature oocytes were retrieved. The total pregnancy rate and implantation rate were 20.5 and 11.5%, respectively.
CONCLUSIONS: The low dose and half duration of GnRHa therapy lessened the suppression of the response of the ovaries to COH compared with the regular long protocol of GnRHa down regulation therapy. This resulted in a low cancellation rate (11.8%), a favorable embryo implantation rate (11.5%), and an acceptable clinical pregnancy rate (20.5%).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893009      PMCID: PMC3455668          DOI: 10.1023/a:1014026220880

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  14 in total

1.  Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders.

Authors:  S L Padilla; K Dugan; V Maruschak; S Shalika; R D Smith
Journal:  Fertil Steril       Date:  1996-04       Impact factor: 7.329

2.  Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age.

Authors:  J P Toner; C B Philput; G S Jones; S J Muasher
Journal:  Fertil Steril       Date:  1991-04       Impact factor: 7.329

3.  Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor-responders in IVF-ET.

Authors:  M Taşdemir; I Taşdemir; H Kodama; J Fukuda; T Tanaka
Journal:  J Obstet Gynaecol Res       Date:  1996-02       Impact factor: 1.730

4.  In vitro fertilization outcome according to age and follicle-stimulating hormone levels on cycle day 3.

Authors:  S Bassil; P A Godin; S Gillerot; J C Verougstraete; J Donnez
Journal:  J Assist Reprod Genet       Date:  1999-05       Impact factor: 3.412

5.  Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol.

Authors:  W Schoolcraft; T Schlenker; M Gee; J Stevens; L Wagley
Journal:  Fertil Steril       Date:  1997-01       Impact factor: 7.329

6.  Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels.

Authors:  D Feldberg; J Farhi; J Ashkenazi; D Dicker; J Shalev; Z Ben-Rafael
Journal:  Fertil Steril       Date:  1994-08       Impact factor: 7.329

7.  Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.

Authors:  R T Scott; D Navot
Journal:  Fertil Steril       Date:  1994-05       Impact factor: 7.329

8.  The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response.

Authors:  Z H Ibrahim; P L Matson; P Buck; B A Lieberman
Journal:  Fertil Steril       Date:  1991-01       Impact factor: 7.329

9.  Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients.

Authors:  C A Benadiva; O Davis; I Kligman; H C Liu; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

10.  Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study.

Authors:  J Dor; D S Seidman; E Amudai; D Bider; D Levran; S Mashiach
Journal:  Hum Reprod       Date:  1995-01       Impact factor: 6.918

View more
  3 in total

Review 1.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

2.  Strategies for Pituitary Down-regulation to Optimize IVF/ICSI Outcome in Poor Ovarian Responders.

Authors:  Ahmed Badawy; Alaa Wageah; Mohamed El Gharib; Ezz Eldin Osman
Journal:  J Reprod Infertil       Date:  2012-07

3.  Prediction and diagnosis of poor ovarian response: the dilemma.

Authors:  Ahmed Badawy; Alaa Wageah; Mohamed El Gharib; Ezz Eldin Osman
Journal:  J Reprod Infertil       Date:  2011-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.